Lilly Stands Firm Against Florida Price Negotiations
Lilly turned its back on Florida's call for supplemental rebates on Zyprexa knowing that it was protected by the new Medicare law. The company eventually reached a deal with the state that allows for price flexibility and supports longer use of the drug. Manufacturers with drugs categorized under Medicare's six protected drug classes could do the same.
You may also be interested in...
Antipsychotics in general-and Lilly's Zyprexa in particular-may be the products taking the biggest hit from health care reform. The only thing worse was the alternative.
Pfizer is discounting its blockbuster brand Lipitor more aggressively. But, thanks to the economics of Medicare Part D, the product is still benefiting from a big net price increase in 2006. Lipitor's performance is some much needed good news for Pfizer--and maybe even better news for the industry as a whole.
Lilly is quietly acknowledging that there will be a pay off from the launch of the new Medicare prescription drug benefit, thanks to the shift of many Zyprexa patients away from the price controlled Medicaid market.